Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC decreased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 15.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,570 shares of the medical research company's stock after selling 14,338 shares during the period. Fisher Asset Management LLC owned 0.28% of Bio-Rad Laboratories worth $26,015,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Simplicity Solutions LLC raised its holdings in Bio-Rad Laboratories by 26.8% during the 3rd quarter. Simplicity Solutions LLC now owns 676 shares of the medical research company's stock worth $242,000 after purchasing an additional 143 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in Bio-Rad Laboratories by 412.5% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 4,100 shares of the medical research company's stock valued at $1,470,000 after buying an additional 3,300 shares during the period. Xponance Inc. boosted its position in Bio-Rad Laboratories by 4.3% during the third quarter. Xponance Inc. now owns 3,296 shares of the medical research company's stock valued at $1,181,000 after acquiring an additional 135 shares during the last quarter. Raymond James & Associates grew its holdings in Bio-Rad Laboratories by 2.3% during the 3rd quarter. Raymond James & Associates now owns 34,732 shares of the medical research company's stock worth $12,450,000 after acquiring an additional 767 shares during the period. Finally, New York State Teachers Retirement System raised its position in shares of Bio-Rad Laboratories by 0.5% in the 3rd quarter. New York State Teachers Retirement System now owns 15,952 shares of the medical research company's stock worth $5,718,000 after acquiring an additional 84 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BIO has been the subject of several recent analyst reports. Royal Bank of Canada decreased their target price on Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating for the company in a research note on Friday, February 16th. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, April 25th. UBS Group raised their price target on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a "buy" rating in a report on Friday, February 16th. Finally, Citigroup lowered shares of Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $468.00.

Bio-Rad Laboratories Stock Up 0.2 %

Shares of Bio-Rad Laboratories stock traded up $0.52 during trading hours on Friday, reaching $279.83. The company's stock had a trading volume of 196,160 shares, compared to its average volume of 222,366. The company has a market capitalization of $7.98 billion, a P/E ratio of -13.02 and a beta of 0.94. The stock's fifty day simple moving average is $318.52 and its two-hundred day simple moving average is $314.71. Bio-Rad Laboratories, Inc. has a one year low of $261.59 and a one year high of $468.45. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The business had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. During the same quarter in the previous year, the business earned $3.31 EPS. The company's quarterly revenue was down 6.7% on a year-over-year basis. On average, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.41 earnings per share for the current year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP Michael Crowley sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the transaction, the executive vice president now directly owns 6,942 shares of the company's stock, valued at $2,332,512. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 17.06% of the company's stock.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.